Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15854067 | 1.00 | THRB (0.39) | THRBMEN1KMT2A | |
| SCHEMBL15854077 | 1.00 | THRB (0.39) | THRBMEN1KMT2A | |
| SCHEMBL852614 | 0.93 | THRB (0.32) | THRBMEN1KMT2A | |
| SCHEMBL853092 | 0.93 | THRB (0.32) | THRBMEN1KMT2A | |
| SCHEMBL852615 | 0.93 | THRB (0.32) | THRBMEN1KMT2A | |
| SCHEMBL22060691 | 0.87 | THRB (0.39) | THRBMEN1KMT2A | |
| SCHEMBL12093041 | 0.86 | — | — | |
| SCHEMBL3900131 | 0.86 | — | — | |
| SCHEMBL18074093 | 0.86 | — | — | |
| SCHEMBL24035146 | 0.83 | THRB (0.33) | THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880033-B1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-06-17 | — | — | EP | disclosed |
| US-9951038-B2 | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951038-B2 | Quinazolin-4(3H)-one-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598411-B2 | Substituted benzimidazole-type piperidine compounds and uses thereof | PURDUE PHARMA L.P. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160002203-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | TADESSE DAWIT (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002203-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | TADESSE DAWIT (US) | 2016-01-07 | — | — | US | disclosed |
| US-20150322066-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-11-12 | — | — | US | disclosed |
| US-20150322066-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. | 2015-11-12 | — | — | US | disclosed |
| US-9085561-B2 | Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9040533-B2 | Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-05-26 | — | — | US | disclosed |
| WO-2014102594-A2 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| WO-2014102592-A2 | OXIME/SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187544-A1 | OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| WO-2014102589-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187535-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | H1-0, H1-3, CACNA1A | THRB 3590/4885MEN1 4725/4885KMT2A 302/4885 |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | THRB 3749/4885MEN1 2991/4885KMT2A 2129/4885 |
| US-20150322066-A1 | SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | H1-0, H1-3, CACNA1A | THRB 3590/4885MEN1 4725/4885KMT2A 302/4885 |
| US-20160002203-A1 | QUINAZOLIN-4(3H)-ONE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | OPRK1, OPRD1, P2RX4 | THRB 3836/4885MEN1 3857/4885KMT2A 2815/4885 |
| US-20140187544-A1 | OXIME-SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QSOX1, OPRK1, OPRD1 | THRB 2130/4885MEN1 4216/4885KMT2A 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.